• DocumentCode
    2481907
  • Title

    P6A-1 Photoacoustic Imaging of Fibrosarcoma Using RGD-Cy 3 as a Targeted Contrast Agent

  • Author

    Mienkina, M.P. ; Friedrich, C.-S. ; Waldeck, J. ; Hensel, K. ; Gerhardt, N.C. ; Bremer, C. ; Hofmann, M. ; Schmitz, G.

  • Author_Institution
    Ruhr-Univ., Bochum
  • fYear
    2007
  • fDate
    28-31 Oct. 2007
  • Firstpage
    2409
  • Lastpage
    2412
  • Abstract
    Photoacoustics (PA) combines the high contrast of optical imaging modalities with the high resolution of clinical ultrasound. Fluorescence mediated tomography (FMT), on the other hand, offers a very high molecular contrast specificity. Therefore, a combination of PA imaging and FMT might be fruitful: e.g. PA imaging could provide valuable a priori information for optical-tomography reconstruction algorithms thereby improving the resolution of FMT. The fusion of PA and FMT will be facilitated by contrast agents that are detectable by both modalities. This study investigates the usage of RGD-Cy 3 as a multimodal contrast agent specific for M21 and HT-1080 tumor cells in vivo (fluorescence reflectance imaging, FRI) and ex vivo (PA). 1.6 muM of RGD-Cy 3 was injected into tumor bearing mice (n=4 M21, n=6 HT-1080). The mice were subjected to in vivo FRI. The FRI showed a typical tracer washout time response, however a statistically significant difference between tumor tissue and muscle tissue could not be shown due to auto-fluorescence and hemoglobin absorption. Similar results were obtained 24 h after the injection of the tracer in biodistribution experiments conducted using harvested organs. Subsequently, the organs were PA imaged using a commercial ultrasound system (Sonix RP) and a Nd:YAG laser (532 nm). The kidney exhibited a mean contrast to the noise-floor of 23.97 dB (plusmn 2.65 standard error of the mean (SEM)), the hearts 23.45 dB (plusmn 0.63 SEM), and the native tumor 26.09 dB. RGD-Cy 3 labeled tumors showed a gain of 0.26 dB (26.35 dB plusmn 0.22 SEM) compared to unlabeled tumors, which was not statistically significant. These results were consistent with in vitro measurements of Cy 3-gelatine mixture phantoms that only showed a 9.4 dB gain compared to the noise- floor for a concentration 81 times higher than in vivo. These findings suggest that RGD-Cy 3 might not be a suitable contrast agent for in vivo PA imaging, although similar fluorochromes like Indocy- anine Green were already successfully used for PA imaging.
  • Keywords
    biomedical optical imaging; biomedical ultrasonics; cancer; fluorescence; optical tomography; photoacoustic effect; tumours; ultrasonic imaging; HT-1080 tumor cells; M21 tumor cells; Nd:YAG laser; RGD-Cy 3; Sonix RP; auto-fluorescence; clinical ultrasound; fibrosarcoma; fluorescence mediated tomography; hemoglobin absorption; in vivo fluorescence reflectance imaging; optical imaging; optical tomography reconstruction algorithm; photoacoustic imaging; targeted contrast agent; tracer washout time response; Fluorescence; Gain; High-resolution imaging; Image resolution; In vivo; Mice; Neoplasms; Optical imaging; Tomography; Ultrasonic imaging;
  • fLanguage
    English
  • Publisher
    ieee
  • Conference_Titel
    Ultrasonics Symposium, 2007. IEEE
  • Conference_Location
    New York, NY
  • ISSN
    1051-0117
  • Print_ISBN
    978-1-4244-1384-3
  • Electronic_ISBN
    1051-0117
  • Type

    conf

  • DOI
    10.1109/ULTSYM.2007.606
  • Filename
    4410179